Drug Guide

Generic Name

Scopolamine

Brand Names Transderm Scop

Classification

Therapeutic: Antiemetic, Anticholinergic

Pharmacological: Muscarinic receptor antagonist

FDA Approved Indications

Mechanism of Action

Scopolamine blocks muscarinic receptors in the central and peripheral nervous system, reducing cholinergic transmission, which decreases nausea and vomiting signals in the brain.

Dosage and Administration

Adult: Apply one patch behind the ear 4 hours before travel, then replace every 72 hours as needed.

Pediatric: Use is not typically recommended for children under 2 years due to safety concerns. Dosing for older children should be individualized based on medical advice.

Geriatric: Use with caution due to increased risk of anticholinergic side effects in older adults.

Renal Impairment: Adjustments are not specifically established; use cautiously.

Hepatic Impairment: Use with caution; hepatic metabolism may be prolonged.

Pharmacokinetics

Absorption: Rapid absorption through intact skin from the transdermal patch.

Distribution: Widely distributed; crosses the blood-brain barrier.

Metabolism: Metabolized in the liver.

Excretion: Excreted primarily in urine.

Half Life: Approximately 9-12 hours.

Contraindications

Precautions

Adverse Reactions - Common

Adverse Reactions - Serious

Drug-Drug Interactions

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor for signs of anticholinergic toxicity, skin reactions at application site, and efficacy in preventing nausea.

Diagnoses:

  • Risk for falls due to dizziness or sedation.
  • Risk for dry mouth.
  • Risk for urinary retention.

Implementation: Apply patch behind the ear at the specified times, ensure skin is clean and dry before application.

Evaluation: Assess for reduction in nausea and side effects; inspect application site regularly.

Patient/Family Teaching

Special Considerations

Black Box Warnings:

Genetic Factors: No known genetic factors affecting use.

Lab Test Interference: None reported.

Overdose Management

Signs/Symptoms: Drowsiness, hallucinations, ataxia, dry mouth, urinary retention, tachycardia.

Treatment: Supportive care, activated charcoal if ingestion is recent, physostigmine (an anticholinesterase) as antidote under specialist supervision.

Storage and Handling

Storage: Store at room temperature, away from heat and light.

Stability: Stable for use until expiration date on the package.

This guide is for educational purposes only and is not intended for clinical use.